Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
Colesevelam (Cholestagel®) has not been endorsed for use within NHS Wales in combination with ezetimibe, with or without a statin, for the treatment of adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia. The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of colesevelam (Cholestagel®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services. |
||
|
||
Medicine details |
||
| Medicine name | colesevelam (Cholestagel®) | |
| Formulation | 625 mg film-coated tablet | |
| Reference number | 668 | |
| Indication | In combination with ezetimibe, with or without a statin, for the treatment of adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia |
|
| Company | Genzyme Therapeutics | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 11/08/2010 | |